Cargando…
Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review
BACKGROUND: Breast cancer surveillance programmes ensure early identification of recurrence which maximises overall survival. Programmes include annual clinical examination and radiological assessment. There remains debate around the value of annual clinical exam in diagnosing recurrent disease/seco...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495471/ https://www.ncbi.nlm.nih.gov/pubmed/37479843 http://dx.doi.org/10.1245/s10434-023-13885-7 |
_version_ | 1785104903573602304 |
---|---|
author | Horan, Jack Reid, Conor Boland, Michael R. Daly, Gordon R. Keelan, Stephen Lloyd, Angus J. Downey, Eithne Walmsley, Adam Staunton, Marie Power, Colm Butt, Abeeda Duke, Deirdre Hill, Arnold D. K. |
author_facet | Horan, Jack Reid, Conor Boland, Michael R. Daly, Gordon R. Keelan, Stephen Lloyd, Angus J. Downey, Eithne Walmsley, Adam Staunton, Marie Power, Colm Butt, Abeeda Duke, Deirdre Hill, Arnold D. K. |
author_sort | Horan, Jack |
collection | PubMed |
description | BACKGROUND: Breast cancer surveillance programmes ensure early identification of recurrence which maximises overall survival. Programmes include annual clinical examination and radiological assessment. There remains debate around the value of annual clinical exam in diagnosing recurrent disease/second primaries. The aim was to assess diagnostic modalities for recurrent breast cancer with a focus on evaluating the role of annual clinical examination. PATIENTS AND METHODS: A prospectively maintained database from a symptomatic breast cancer service between 2010–2020 was reviewed. Patients with biopsy-proven recurrence/second breast primary were included. The primary outcome was the diagnostic modality by which recurrences/secondary breast cancers were observed. Diagnostic modalities included (i) self-detection by the patient, (ii) clinical examination by a breast surgeon or (iii) radiological assessment. RESULTS: A total of 233 patients were identified and, following application of exclusion criteria, a total of 140 patients were included. A total of 65/140 (46%) patients were diagnosed clinically, either by self-detection or clinical examination, while 75/140 (54%) were diagnosed radiologically. A total of 59/65 (91%) of patients clinically diagnosed with recurrence presented to the breast clinic after self-detection of an abnormality. Four (6%) patients had cognitive impairment and recurrence was diagnosed by a carer. Two (3%) patients were diagnosed with recurrence by a breast surgeon at clinical examination. The median time to recurrence in all patients was 48 months (range 2–263 months). CONCLUSION: Clinical examination provides little value in diagnosing recurrence (< 5%) and surveillance programmes may benefit from reduced focus on such a modality. Regular radiological assessment and ensuring patients have urgent/easy access to a breast clinic if they develop new symptoms/signs should be the focus of surveillance programmes. |
format | Online Article Text |
id | pubmed-10495471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-104954712023-09-13 Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review Horan, Jack Reid, Conor Boland, Michael R. Daly, Gordon R. Keelan, Stephen Lloyd, Angus J. Downey, Eithne Walmsley, Adam Staunton, Marie Power, Colm Butt, Abeeda Duke, Deirdre Hill, Arnold D. K. Ann Surg Oncol Breast Oncology BACKGROUND: Breast cancer surveillance programmes ensure early identification of recurrence which maximises overall survival. Programmes include annual clinical examination and radiological assessment. There remains debate around the value of annual clinical exam in diagnosing recurrent disease/second primaries. The aim was to assess diagnostic modalities for recurrent breast cancer with a focus on evaluating the role of annual clinical examination. PATIENTS AND METHODS: A prospectively maintained database from a symptomatic breast cancer service between 2010–2020 was reviewed. Patients with biopsy-proven recurrence/second breast primary were included. The primary outcome was the diagnostic modality by which recurrences/secondary breast cancers were observed. Diagnostic modalities included (i) self-detection by the patient, (ii) clinical examination by a breast surgeon or (iii) radiological assessment. RESULTS: A total of 233 patients were identified and, following application of exclusion criteria, a total of 140 patients were included. A total of 65/140 (46%) patients were diagnosed clinically, either by self-detection or clinical examination, while 75/140 (54%) were diagnosed radiologically. A total of 59/65 (91%) of patients clinically diagnosed with recurrence presented to the breast clinic after self-detection of an abnormality. Four (6%) patients had cognitive impairment and recurrence was diagnosed by a carer. Two (3%) patients were diagnosed with recurrence by a breast surgeon at clinical examination. The median time to recurrence in all patients was 48 months (range 2–263 months). CONCLUSION: Clinical examination provides little value in diagnosing recurrence (< 5%) and surveillance programmes may benefit from reduced focus on such a modality. Regular radiological assessment and ensuring patients have urgent/easy access to a breast clinic if they develop new symptoms/signs should be the focus of surveillance programmes. Springer International Publishing 2023-07-21 2023 /pmc/articles/PMC10495471/ /pubmed/37479843 http://dx.doi.org/10.1245/s10434-023-13885-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Breast Oncology Horan, Jack Reid, Conor Boland, Michael R. Daly, Gordon R. Keelan, Stephen Lloyd, Angus J. Downey, Eithne Walmsley, Adam Staunton, Marie Power, Colm Butt, Abeeda Duke, Deirdre Hill, Arnold D. K. Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review |
title | Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review |
title_full | Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review |
title_fullStr | Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review |
title_full_unstemmed | Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review |
title_short | Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review |
title_sort | assessing mode of recurrence in breast cancer to identify an optimised follow-up pathway: 10-year institutional review |
topic | Breast Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495471/ https://www.ncbi.nlm.nih.gov/pubmed/37479843 http://dx.doi.org/10.1245/s10434-023-13885-7 |
work_keys_str_mv | AT horanjack assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT reidconor assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT bolandmichaelr assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT dalygordonr assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT keelanstephen assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT lloydangusj assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT downeyeithne assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT walmsleyadam assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT stauntonmarie assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT powercolm assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT buttabeeda assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT dukedeirdre assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview AT hillarnolddk assessingmodeofrecurrenceinbreastcancertoidentifyanoptimisedfollowuppathway10yearinstitutionalreview |